PMID- 27713843
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2150-0878 (Print)
IS  - 2150-0886 (Electronic)
IS  - 2150-0878 (Linking)
VI  - 7
IP  - 1
DP  - 2016 Jan-Feb
TI  - Tyrosine Kinase Inhibitors for the Treatment of Chronic-Phase Chronic Myeloid 
      Leukemia: Long-Term Patient Care and Management.
PG  - 42-54
AB  - Several tyrosine kinase inhibitors (TKIs) are now approved for the treatment of 
      chronic myeloid leukemia in chronic phase. The efficacy of these drugs has been 
      repeatedly demonstrated, as has their tolerability in most patients. However, 
      late and chronic toxicities become an important issue for many patients facing 
      long-term TKI exposure. For patients on long-term imatinib, gastrointestinal 
      events, fluid retention, muscle cramps, fatigue, and hepatotoxicity are among the 
      most common and most clinically relevant adverse events (AEs). A few of these 
      have also emerged as important AEs with some of the newer TKIs. Distinct 
      long-term toxicity concerns have emerged for dasatinib (pleural effusion, 
      pulmonary hypertension, headache, and dyspnea) and nilotinib (rash, headache, 
      myalgia, alopecia, and hyperglycemia), whereas due to the recent approval of 
      bosutinib and ponatinib, their long-term toxicity profiles have not been fully 
      characterized. Clinical experience with each of these drugs is accumulating, and 
      ensuring proper adherence and monitoring for potential AEs is essential for 
      effective treatment.
FAU - Bauer, Stephanie
AU  - Bauer S
AD  - 1Department of Internal Medicine, Washington University, St. Louis, Missouri; 
      2Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, Massachusetts; 
      3Department of Internal Medicine and Department of Hematology/Oncology, 
      University of Michigan Health System, Ann Arbor, Michigan.
FAU - Buchanan, Susan
AU  - Buchanan S
AD  - 1Department of Internal Medicine, Washington University, St. Louis, Missouri; 
      2Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, Massachusetts; 
      3Department of Internal Medicine and Department of Hematology/Oncology, 
      University of Michigan Health System, Ann Arbor, Michigan.
FAU - Ryan, Irene
AU  - Ryan I
AD  - 1Department of Internal Medicine, Washington University, St. Louis, Missouri; 
      2Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, Massachusetts; 
      3Department of Internal Medicine and Department of Hematology/Oncology, 
      University of Michigan Health System, Ann Arbor, Michigan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160101
PL  - United States
TA  - J Adv Pract Oncol
JT  - Journal of the advanced practitioner in oncology
JID - 101550346
PMC - PMC5045277
EDAT- 2016/10/08 06:00
MHDA- 2016/10/08 06:01
PMCR- 2016/01/01
CRDT- 2016/10/08 06:00
PHST- 2016/10/08 06:00 [entrez]
PHST- 2016/10/08 06:00 [pubmed]
PHST- 2016/10/08 06:01 [medline]
PHST- 2016/01/01 00:00 [pmc-release]
AID - 10.6004/jadpro.2016.7.1.3 [doi]
PST - ppublish
SO  - J Adv Pract Oncol. 2016 Jan-Feb;7(1):42-54. doi: 10.6004/jadpro.2016.7.1.3. Epub 
      2016 Jan 1.